The source and research and development background of obeticholic acid

Obeticholic acid (Obeticholic acid) is an innovative drug developed by Intercept Pharmaceuticals and put on the market for the first time. Intercept Pharmaceuticals is a biopharmaceutical company focused on the treatment of chronic liver diseases and committed to developing new treatments, headquartered in the United States. The research and development process of obeticholic acid is based on in-depth research on the farnesoid X receptor (FXR). As a key nuclear receptor, FXR plays a vital role in bile acid metabolism and inflammation regulation.

In 2016, obeticholic acid was approved by the U.S. Food and Drug Administration (FDA) and became a new option for the treatment of primary biliary cholangitis (PBC). This milestone marks new hope for many patients who have failed to respond to traditional treatments. Clinical studies have shown that when obeticholic acid is combined with ursodeoxycholic acid (UDCA), it can significantly reduce alkaline phosphatase (ALP) levels, an important biomarker for assessing liver function. Approximately 40% of patients treated with UDCA failed to achieve adequate ALP reduction, and the application of obeticholic acid effectively improved this situation.

The mechanism of action of obeticholic acid is mainly by binding to farnesolX receptor, reducing the production of bile acids and promoting the excretion of bile acids from the liver. This effect not only helps reduce the burden on the liver, but also improves the patient's overall health. However, although obeticholic acid shows significant efficacy, it also has certain adverse reactions, including skin itching, fatigue, abdominal pain, joint pain, dizziness, and constipation. Therefore, doctors need to conduct a comprehensive evaluation of patients when using this drug to ensure a safe and effective treatment plan.

Reference materials:https://pharmaceutical-journal.com/article/news/obeticholic-acid-gets-us-approval-for-rare-liver-disease